key: cord-1006245-oiwl29dy
authors: Roukens, A. H. E.; Konig, M.; Dalebout, T.; Tak, T.; Azimi, S.; Kruize, Y.; Pothast, C. R.; Hagedoorn, R. S.; Arbous, S. M.; Zhang, J. L. H.; Verheij, M.; Prins, C.; Does, A. M.; Hiemstra, P. S.; Vries, J. J. C.; Janse, J. J.; Roestenberg, M.; Myeni, S. K.; Kikkert, M.; Heemskerk, M. H. M.; Yazdanbakhsh, M.; Smits, H. H.; Jochems, S. P.; BEAT-COVID group,; group, COVID-19 LUMC
title: Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19
date: 2021-04-22
journal: nan
DOI: 10.1101/2021.04.19.21255727
sha: 7a33c0179cabe9d2275e4b07907a8d4d446d0c75
doc_id: 1006245
cord_uid: oiwl29dy

The immune system plays a major role in Coronavirus Disease 2019 (COVID-19) pathogenesis, viral clearance and protection against re-infection. Immune cell dynamics during COVID-19 have been extensively documented in peripheral blood, but remain elusive in the respiratory tract. We performed minimally-invasive nasal curettage and mass cytometry to characterize nasal immune cells of COVID-19 patients during and 5-6 weeks after hospitalization. Contrary to observations in blood, no general T cell depletion at the nasal mucosa could be detected. Instead, we observed increased numbers of nasal granulocytes, monocytes, CD11c+ NK cells and exhausted CD4+ T effector memory cells during acute COVID-19 compared to age-matched healthy controls. These pro-inflammatory responses were found associated with viral load, while neutrophils also negatively correlated with oxygen saturation levels. Cell numbers mostly normalized following convalescence, except for persisting CD127+ granulocytes and activated T cells, including CD38+ CD8+ tissue-resident memory T cells. Moreover, we identified SARS-CoV-2 specific CD8+ T cells in the nasal mucosa in convalescent patients. Thus, COVID-19 has both transient and long-term effects on the immune system in the upper airway.

Individuals infected with SARS-CoV-2 suffer from a wide range of symptoms, ranging from 19 none to fever, cough and dyspnea and severe acute respiratory distress syndrome, which can 20 culminate in death 1 . The immune cell perturbations during COVID-19 have been described 21

extensively in blood, with changes observed in almost all immune cell populations that often 22

could be linked to disease severity. A global depletion of peripheral blood T cells has been 23

proposed to be a hallmark of COVID-19 2, 3 . At the same time, neutrophil numbers are strongly 24

increased and an increased neutrophil to lymphocyte ratio is associated with poor prognosis 25 4 . Natural killer (NK) cells show an activated profile, associating with disease severity 5 . 26 Myeloid cells show an aberrant profile with increased proliferation and altered functionality 6, 7 . 27

The B cell compartment is characterized by oligoclonal expansion of plasmablasts and 28 extrafollicular B cells 8, 9 . Eosinophils were found to be decreased in blood in most patients at 29

time of hospital admission 10 . However, eosinophils might expand during hospitalization and 30

show upregulated levels of the homing marker CD62L and activation profiles, which was found 31

to precede lung hyperinflammation 11 . 32

Although SARS-CoV-2 mainly replicates in the respiratory tract, and lower respiratory tract 33

complications are major drivers of morbidity and mortality, it is unclear to what extent 34

immunological dynamics observed in blood can be translated to the respiratory tract. Indeed, 35

cytokines and antibodies do not seem to correlate between the nasopharynx and peripheral 36 blood during COVID-19 12 . Several studies already investigated mucosal immune responses 37

using either bronchoalveolar lavage (BAL) 13 or nasopharyngeal and oropharyngeal swabs 14 38 from hospitalized patients, demonstrating increased neutrophil levels and activated alveolar 39 macrophages/monocytes during COVID-19. T cell recruitment to the respiratory tract might be 40 beneficial, as an expansion of CD8 + T cell receptor (TCR) clones in BAL has been reported in 41 moderate compared to critical cases 13 . Another study with severe COVID-19 patients found 42 that increased CD4 + T cells in tracheal aspirates associated with survival 15 . In addition to 43 these findings, several other studies have used nasopharyngeal swabs (NPS) to analyse local 44 responses 16, 17 . However, NPS collect cells only very superficially and mainly provide epithelial 45

and luminal infiltrating cells such as neutrophils and monocytes, while other immune cells, 46

such as T cells are incompletely captured. In contrast, BAL samples and tracheal aspirates 47 provide a clear picture of the lower airways 18-21 , but are difficult to collect longitudinally, after 48 recovery, or from healthy controls and patients that do not require intubation. Moreover, 49 studies performed on tissue are usually done in severe patients that died from the infection, 50

which creates a bias in the outcomes. As a result, we still have limited understanding of how 51 COVID-19 affects mucosal immunity 22 . In the current study, we aimed to characterize immune 52 cell dynamics in the upper respiratory tract mucosa during the acute phase and early and later 53 recovery of COVID-19 disease and assess whether alterations persist during convalescence. 54

To this end, we performed a prospective observational cohort study, for which we recruited 55 patients with PCR-confirmed SARS-CoV-2 infection after hospital admission (Figure 1a ).

Nasal curettage samples from 20 patients during hospitalization with up to 4 samples per 57 patient were collect and analysed in-depth using mass cytometry. The earliest samples were 58 collected 11 days after symptom onset, which corresponded to 2 days after admission, while 59 the latest sample was collected 82 days after onset (61 days after admission there is no increase or decrease of total T cell numbers in the nasal mucosa is in contrast with 95 the general T cell depletion that has been observed in peripheral blood 2,3,6,7,23 . increased during acute infection and ERS compared to convalescent patients and to healthy 101

donors. As expected, subsets of granulocytes were also increased, although with slightly 102 different dynamics during acute infection: CD16 hi neutrophils were elevated during acute stage 103

and to a lesser degree in ERS (median of 121.7x and 12.8x increased compared to healthy 104 donors, respectively). CD16 dim neutrophils were even more strongly increased during acute 105 infection (median 256.8x) and ERS (median 11.9x). Such CD16 dim neutrophils might 106 correspond to activated neutrophils as previously they have been shown to correlate with 107 nasal myeloperoxidase levels and/or they might be related to immature banded neutrophils, 108

recently released from the bone marrow 24,25 . Furthermore, CD16 neg granulocytes, which may 109 in part consist of eosinophils, were increased compared to controls 254.1x and 24.3x during 110 acute stage and ERS, respectively. Although there was no overall change in CD4 + T cell 111

numbers, there was an significant increase (median 18.0x) in effector memory (EM, CCR7 -112 CD45RO + ) CD4 + T cells during the acute phase. And although not statistically significant, CD8 + 113

T effector memory cells re-expressing CD45RA (EMRA: CCR7 -CD45RA + ) also showed a 114 trend towards increased levels during acute infection compared to healthy donors (median 115

10.4x increased during acute infection). These findings agree with reports from peripheral 116 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; blood T cell responses during SARS-CoV-2 infection describing that more specific CD4 + T 117 cells are being induced than CD8 + T cells, and that the majority of specific CD8 + T cells are of 118 a T EMRA phenotype 26, 27 . Levels of these short-lived effector cells returned more or less to 119 numbers observed in healthy donors during ERS and convalescence. Finally, an additional 120 population that was increased in hospitalized patients (both acute and ERS), compared to 121 convalescent stage and healthy donors, were the CD11c + NK cells, which might indicate a NK 122

cell population with increased interferon-producing capacity and effector function 28 . Thus, 123

dynamic recruitment of various adaptive and innate populations mediating inflammation and 124 antiviral function to the upper respiratory tract was observed during hospitalization with cell 125 type numbers in convalescence that closely resembled levels measured in healthy donors. Of 126 note, we did not observe an increase in nasal B cells in hospitalized patients, which 127

corroborates observations that mucosal antibody levels seem reduced compared to systemic 128 titres in hospitalized patients 12, 29 . 129

Next, we analysed whether immune cell types correlated with each other as well as with 130

clinical characteristics during COVID-19 ( Figure 3c ). Focusing on samples from hospitalized 131 patient, a clear cluster of subsets with positively correlated frequencies was observed, which 132

included monocyte subsets, granulocyte subsets and CD4 + T EM and CD8 + T EMRA cells.

Most of these subsets negatively correlated with days since symptom onset and hospital 134

admission (see also the time-based plots in Supplementary figure 1), indicating that during 135

longer hospitalization the numbers of these cells gradually return to normal levels. Among all 136

cell types, the monocyte subsets, CD16 neg granulocytes and CD16 dim neutrophils correlated 137

positively with viral load (Figure 3c ), suggesting that SARS-CoV-2 virus infection dose-138

dependently induced nasal recruitment of various immune subsets. We also correlated cell 139 numbers with measurements of disease severity obtained at the same day as nasal sampling, 140

including breathing rate, oxygen saturation and serum CRP concentrations. This revealed that 141

CD16 hi neutrophils numbers, as well as total numbers of granulocytes, in nasal mucosa 142

negatively correlated with oxygen saturation levels. As expected, oxygen saturation also 143 negatively associated with applied oxygen flow, but not with viral load. This suggests that 144

fluctuations in viral titers are not related to disease worsening, while the enhanced presence 145 of nasal granulocyte populations is, similar to what has been described for granulocyte 146 numbers in peripheral blood. To understand whether factors like sex, co-morbidities and 147 medication were drivers of nasal immune profiles, we performed multi-dimensional scaling 148 using all cell subsets (Supplementary figure 2). Acute patients clearly clustered separately 149 from healthy donors and convalescent patients, with ERS patients intermediate. Therefore, 150

we visualized covariates separately per group (acute, ERS, convalescent, healthy), showing 151

there was no clear clustering based on any of these covariates, although larger sample sizes 152 might be needed to conclusively exclude any such effects. 153

Subsequently, we looked more closely at phenotypic expression profiles on the differentially 154 abundant cell clusters and to what extent these profiles normalized after hospital discharge. 155

Although all monocyte subsets significantly increased during acute infection, patients had 156 relatively more CD163 + and fewer CD163 + CD206 + monocytes/macrophages compared to 157 healthy donors, which normalized during recovery ( Figure 4a ). These CD206 + cells are likely 158 fully differentiated tissue-resident macrophages 30 . CD163 + monocytes were also found 159 abundantly in peripheral blood of COVID-19 patients as well as in autopsy lungs and likely 160 represent a recently recruited monocyte population, a hypothesis that was supported by 161 trajectory analysis (Figure 4b ) 15 . Of note, we did not observe non-classical or transitional is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021.

reported during severe COVID-19 31,32 . Our results suggest that these cells may rapidly seed 168 the upper airway mucosa where they might further differentiate and acquire a macrophage 169

phenotype. CD163 + CD206 + monocytes/macrophages also expressed elevated levels of the 170 IL-3 receptor CD123 during both acute phase and ERS, while CD163 + and CD163monocyte 171

subsets generally lacked CD123. The expression of CD123 on tissue macrophages has been 172 previously described in patients with histiocytic necrotizing lymphadenitis 33 . The functional 173

consequences of this upregulation of the IL3R on nasal macrophages during COVID-19 174 remain to be elucidated, but this finding further supports the importance of the IL-3/IL3-R axis 175

in COVID-19 34 . 176

We then investigated more closely CD16granulocytes, by further grouping them into 7 sub-177 clusters (Figure 4d ). Sub-cluster 1, characterized by increased CD127 expression, was 178 significantly increased in patients during hospitalization (median 28.3%) but also during 179

convalescence (median 22.2%) compared to healthy donors (median 5.8%, Figure 4e ,f). It 180 has been shown that engagement of IL-7 with its receptor CD127 on eosinophils leads to 181

increased survival and activation of eosinophils; and in airway allergen challenge in allergic 182 asthmatics, IL-7 levels in BAL strongly correlated with eosinophils 35 . Thus while total numbers 183 of granulocytes returned to similar levels as observed in healthy donors, alterations in their 184

phenotype, and possibly their functionality, remained visible during convalescence. The half-185

life of granulocytes is in the region of hours to days, suggesting either an ongoing recruitment 186 of altered cells or the continued local perturbation after or during entering the respiratory 187 mucosa 35 . 188

The subset of CD4 + EM T cells was also increased during acute infection. To investigate their 189 phenotype more closely, we analysed the expression of markers of activation (CD38, HLA-190 DR), exhaustion (PD1) or inhibition (CTLA-4) on these cells (Figure 5a ). CD38 and CTLA4 191

were increased during the acute phase, but normalized at later timepoints, while HLA-DR and 192

PD1 remained expressed at a higher level even during convalescence as compared to healthy 193

donors. This induction of regulatory and inhibitory markers mirrors what has been described 194

in blood and likely reflects attempts of the immune system to restrain excessive activation.

Finally, we aimed to assess whether long-term protective CD8 + T cell immunity develops in 196 nasal mucosa to serve as gatekeepers against re-infections. Mouse models have shown that 197 nasal CD8 + tissue-resident memory (TRM) T cells specific for influenza persisted in nasal 198 mucosa following infection and efficiently controlled secondary infections 36 . The majority of 199 nasal CD8 + T cells in our samples highly expressed CD69, which is used to define resident-200 memory T cells 37 , while very few naïve CD8 + T cells were present. Although it is possible that 201 some activated CD8 + T cells upregulate CD69 without being true TRM, the cluster of CD8 + 202 TRM expressed very little KLRG1, which is congruent with a TRM phenotype (Figure 1c ) 38 . 203

Sub-clustering of CD8 + TRM showed variable expression of activation markers CD38, HLA-204 DR and Tbet (Figure 5b ). Within this embedding, CD8 + TRM from acute phase, ERS, 205 convalescent patients and controls clustered differentially, indicative of altered phenotypes 206 during and following COVID-19 ( Figure 5c ). Indeed, sub-cluster frequencies significantly 207 differed between the groups (Figure 5d , e). Sub-cluster 5, marked by expression of HLA-DR, 208

Tbet and CD38, was increased in hospitalized patients, while sub-cluster 3, expressing only 209

HLA-DR and CD38, was higher in convalescent patients compared to healthy donors, as were 210

all CD38 + TRMs. Thus CD8 + TRM had an increased activation profile, which persisted at least 211 5-6 weeks after hospital discharge. To demonstrate antigen specificity, we then attempted to 212 compare the T cell receptor (TCR) repertoire in nasal samples from convalescent patients with 213

SARS-CoV-2 reactive CD8 + and CD4 + T cells isolated from paired peripheral blood 214 (Supplementary figure 4) . For one severe, convalescent patient we obtained >10 unique TCRs 215 from both nasal cells and sorted SARS-CoV-2 specific peripheral blood cells (Supplementary 216 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.19.21255727 doi: medRxiv preprint figure 5 ). The TCR repertoire in the nasal mucosa of this patient was broad (218 unique TCRs), 217

including one dominant TCR accounting for 12.2% of all TCR reads. This TCR clone was also 218 present in paired peripheral blood SARS-CoV-2 specific CD8 + T cells (4% of reads), but not 219 in sorted CD4 + T cells (Figure 5f ). As this sample was collected 2 months after viral clearance 220

and 80.4% of the nasal CD8 + T cells for this patient were of a TRM phenotype (Figure 5g ), 221

this indicates that antigen-specific tissue-resident memory was induced. Of note, the number 222 of unique SARS-CoV-2 specific TCRs detected and their overlap between nose and peripheral 223 blood might be underestimated as blood CD8 + T cells were isolated based on reactivity 224

towards structural proteins, while CD8 + T cell reactivity is also directed against non-structural 225 proteins in severe COVID-19 patients [39] [40] [41] . Taken together, we demonstrated SARS-CoV-2 226 specific CD8 + T cells can persist in the nasal mucosa months after viral clearance, based on 227 their activated phenotype and overlapping TCR clonotype with SARS-CoV-2 reactive CD8 + T 228 cells in blood. This is suggestive of the establishment of local protective immune memory 229

responses that could rapidly control and attenuate re-infections by SARS-CoV-2. oxygen saturation in blood. We show several similarities with reports from blood, including a 237 strong CD4 + T EM cell response marked by markers of activation, but also exhaustion and 238

inhibition, as well as the presence of HLA-DR low monocyte subsets in the nasal mucosa. A 239 striking difference from studies characterizing blood was the absence of a general 240 lymphopenia in the nasal mucosa. We also provided further characterization of cellular 241 subsets infiltrating the mucosa during disease, such as CD11c + NK cells, CD123-expressing 242 differentiated macrophages and CD127 expression on CD16granulocytes. During early and 243

later recovery stages of disease most of the cell numbers progressively returned to levels 244

comparable to age-matched healthy donors. However, several phenotypic changes in nasal 245

immune populations persisted even during recovery. For example CD127-expressing 246 granulocytes remained elevated during convalescence, while also residual increased 247 activation of CD4 + and CD8 + T cells after hospital discharge was observed. Moreover, by 248

comparing nasal TCR clonotypes with antigen-specific cells from blood, we were able to 249 demonstrate that SARS-CoV-2 specific CD8 + T cells can seed the nasal tissue and these We thank all patients and healthy volunteers for taking part in this study. This work was 261 supported by a MKMD-COVID-19 grant (no. 114025007) from ZonMW and Proefdiervrij. This 262 work was also supported by Wake Up To Corona crowdfunding by Leids Universitair Fonds.

SPJ is supported by a LUMC Gisela Thier Fellowship. Figure 1 was partly made with 264 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted . Samples were incubated for 30' at room temperature and then washed with 4mL Cell 317 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ;

Staining Buffer (Fluidigm). Cells were spun 5' at 800xg, supernatant removed and 318 resuspended and combined into 3mL of Perm/Wash. Cells were spun again 5' at 800xg and 319

were resuspended in 45µL Perm/Wash. FcR block (Biolegend, 5µL) and heparin (0.5µL, 320

100U/mL) were added to prevent aspecific binding of antibodies and cells were incubated for 321 20' at room temperature 47 . Then 50µL of antibody cocktail (Table S1 ) was added, followed by 322 a 45' incubation at room temperature. Cells were then washed twice with 2mL Cell Staining 323

Buffer and spun down for 5' at 800xg. DNA was then stained overnight at 4°C using 1mL Fix 

PBMCs from convalescent COVID-19 patients were isolated from fresh whole blood using 354

Ficoll-Isopaque and cryopreserved until further use. PBMCs were thawed and immediately 355 used for overnight stimulation assay. For the stimulation assay, 1x10⁶ PBMCs were seeded CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ;

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.19.21255727 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.19.21255727 doi: medRxiv preprint

of Intensive Care, LUMC

Internal Medicine, Thrombosis and Hemostasis, LUMC 8. Dept. of Medical Microbiology, LUMC 9. Dept. of Infectious Diseases, LUMC 10. Dept. of Biomedical Data Sciences, LUMC 11. Center for Proteomics and Metabolomics, LUMC 12. Division of Systems Biomedicine and Pharmacology

& COVID-19 LUMC group (IR): Josine A. Oud

Jeanette Wigbers 2

Epidemiological and clinical characteristics of 99 cases of 2019 novel 400 coronavirus pneumonia in Wuhan, China: a descriptive study

Longitudinal analyses reveal immunological misfiring in severe COVID-19. 403

Impaired type I interferon activity and inflammatory responses in severe 405 COVID-19 patients

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 407 coronavirus disease in the early stage

Natural killer cell immunotypes related to COVID-19 disease severity

Longitudinal immune profiling reveals key myeloid signatures associated 412 with COVID-19

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell 414 Compartment

Comprehensive mapping of immune perturbations associated with 416 severe COVID-19

Extrafollicular B cell responses correlate with neutralizing antibodies 418 and morbidity in COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Systems-Level Immunomonitoring from Acute to Recovery Phase of 423 Severe COVID-19

Distinct systemic and mucosal immune responses to SARS-CoV-2

Single-cell landscape of bronchoalveolar immune cells in patients with

COVID-19 severity correlates with airway epithelium-immune cell 429 interactions identified by single-cell analysis

Analysis of respiratory and systemic immune responses in COVID-19 432 reveals mechanisms of disease pathogenesis

Hypertension delays viral clearance and exacerbates airway 435 hyperinflammation in patients with COVID-19

Immune cell residency in the nasal mucosa and COVID-19 severity across 438 the age range

Broncho-alveolar inflammation in COVID-19 patients: a correlation with 441 clinical outcome

Discriminating mild from critical COVID-19 by innate and adaptive immune 443 single-cell profiling of bronchoalveolar lavages

Clonal expansion and activation of tissue-resident memory-like Th17 cells 446 expressing GM-CSF in the lungs of severe COVID-19 patients

Phenotype for activated tissue macrophages in histiocytic necrotizing 478 lymphadenitis

Interleukin-3 is a predictive marker for severity and outcome during SARS-480

CoV-2 infections

Potential contribution of IL-7 to allergen-induced eosinophilic airway 483 inflammation in asthma

Resident memory CD8(+) T cells in the upper respiratory tract prevent 486 pulmonary influenza virus infection

Location, location, location: Tissue resident memory T 489 cells in mice and humans

KLRG1(+) Effector CD8(+) T Cells Lose KLRG1, Differentiate 491 into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 494 COVID-19 Disease and Unexposed Individuals

Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize 497 Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in 500 UK convalescent individuals following COVID-19

Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates 503 Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection 504 Compared to Nasal Wash

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV 507 infection

Inflammation induced by influenza virus impairs human innate immune 509 control of pneumococcus

A Universal Live Cell Barcoding-Platform for 512

Palladium-based mass tag cell barcoding with a doublet-filtering scheme 515 and single-cell deconvolution algorithm

Heparin reduces nonspecific eosinophil staining 518 artifacts in mass cytometry experiments

Automatically Cleans Mass Cytometry (CyTOF) FCS files

CATALYST: 522 Cytometry dATa anALYSis Tools

Minimizing Batch Effects in Mass Cytometry Data

Cytosplore: Interactive Immune Cell Phenotyping for Large Single

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid 528 leukemia

Smart-seq2 for sensitive full-length transcriptome profiling in single cells

Comprehensive Integration of Single-Cell Data

 CoV-2  449 pneumonia. Nature 590, doi:10.1038/s41586-020-03148-w (2021 showing nasal CD8 + T cell composition for patient with dominant SARS-CoV-2 specific clone. 619

Naive and EM cells were too infrequent to be visible and are not labeled for this sample. 620